Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Equity Ratio (2022 - 2025)

Corvus Pharmaceuticals has reported Equity Ratio over the past 4 years, most recently at 0.89 for Q3 2025.

  • Quarterly results put Equity Ratio at 0.89 for Q3 2025, up 322.69% from a year ago — trailing twelve months through Sep 2025 was 0.89 (up 322.69% YoY), and the annual figure for FY2024 was 0.47, down 44.34%.
  • Equity Ratio for Q3 2025 was 0.89 at Corvus Pharmaceuticals, down from 0.9 in the prior quarter.
  • Over the last five years, Equity Ratio for CRVS hit a ceiling of 0.9 in Q2 2025 and a floor of 0.21 in Q3 2024.
  • Median Equity Ratio over the past 4 years was 0.84 (2023), compared with a mean of 0.78.
  • Biggest five-year swings in Equity Ratio: tumbled 75.26% in 2024 and later surged 322.69% in 2025.
  • Corvus Pharmaceuticals' Equity Ratio stood at 0.82 in 2022, then grew by 3.27% to 0.85 in 2023, then crashed by 44.34% to 0.47 in 2024, then skyrocketed by 88.69% to 0.89 in 2025.
  • The last three reported values for Equity Ratio were 0.89 (Q3 2025), 0.9 (Q2 2025), and 0.83 (Q1 2025) per Business Quant data.